 Doxorubicin
"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Doxil- Doxil
- Ortho Biotech Brand of Doxorubicin Hydrochloride
Doxorubicin NC- Doxorubicin NC
- Neocorp Brand of Doxorubicin Hydrochloride
Doxotec- Doxotec
- Columbia Brand of Doxorubicin Hydrochloride
Farmiblastina- Farmiblastina
- Kenfarma Brand of Doxorubicin Hydrochloride
Myocet- Myocet
- Elan Brand of Doxorubicin Hydrochloride
Onkodox- Onkodox
- Onkoworks Brand of Doxorubicin Hydrochloride
Ribodoxo- Ribodoxo
- ribosepharm Brand of Doxorubicin Hydrochloride
Rubex- Rubex
- Bristol-Myers Squibb Brand of Doxorubicin Hydrochloride
Adriblastin- Adriblastin
- Pfizer Brand of Doxorubicin Hydrochloride
- Adriblastina
- Adriblastine
- Adriablastin
- Adriablastine
Adriamycin- Adriamycin
- Bedford Brand of Doxorubicin Hydrochloride
Adrimedac- Adrimedac
- medac Brand of Doxorubicin Hydrochloride
Caelyx- Caelyx
- Schering Brand of Doxorubicin Hydrochloride
- Schering-Plough Brand of Doxorubicin Hydrochloride
- Essex Brand of Doxorubicin Hydrochloride
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
- cell pharm Brand of Doxorubicin Hydrochloride
Doxolem- Doxolem
- Lemery Brand of Doxorubicin Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in Harvard Catalyst Profiles by year, and whether "Doxorubicin" was a major or minor topic of these publication.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, Kahl BS, Advani R, Hong F, Horning SJ. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol. 2012 Sep 1; 30(25):3119-26.
-
Goldberg JM, Scully RE, Sallan SE, Lipshultz SE. Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2012 Jul; 34(5):395-7.
-
Al-Quthami AH, Jumean M, Kociol R, Pham DT, Kiernan M, DeNofrio D, Kapur NK. Eptifibatide for the treatment of HeartMate II left ventricular assist device thrombosis. Circ Heart Fail. 2012 Jul 1; 5(4):e68-70.
-
Darrabie MD, Arciniegas AJ, Mantilla JG, Mishra R, Vera MP, Santacruz L, Jacobs DO. Exposing cardiomyocytes to subclinical concentrations of doxorubicin rapidly reduces their creatine transport. Am J Physiol Heart Circ Physiol. 2012 Sep 1; 303(5):H539-48.
-
Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012 Jun 27; 307(24):2609-16.
-
del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2012 Sep; 126(3):369-74.
-
Giardino AA, Shinagare AB, Shinagare SA, Dewar R, Weckstein D, Mauch P, Ramaiya NH, Freedman AS. Primary bone lymphoma involving bilateral tibia. Am J Hematol. 2012 Sep; 87(9):924-5.
-
Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Aug 1; 83(5):e647-54.
-
Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW, Sparano JA. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012 Jul; 134(2):683-92.
-
Delaney TF. Radiation therapy: neoadjuvant, adjuvant, or not at all. Surg Oncol Clin N Am. 2012 Apr; 21(2):215-41.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|